WHO ICTRP trial
Strategies in the treatment of conbercept plus PRP for diabetic retinopathy: a…
ChiCTR2200060038 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2200060038 |
|---|---|
| Public title | Strategies in the treatment of conbercept plus PRP for diabetic retinopathy: a randomized controlled clinical trial |
| Scientific title | Strategies in the treatment of conbercept plus PRP for diabetic retinopathy: a randomized controlled clinical trial |
| Primary sponsor | The Second Affiliated Hospital of Xi'an Jiaotong University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | diabetic retinopathy |
| Interventions | IVC+PRP group:Standard PRP therapy was followed by intravitreal injection (IVC) of compacept;PRP+IVC group:The standard PRP is given before intravitreal conbercept |
| Registration date | May 15, 2022 |
| Target size | IVC+PRP group:52;PRP+IVC group:52 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: